ArticleMedicine2025
Idiopathic multicentric Castleman disease resembling autoimmune diseases: A case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Snapshot Look at Castleman Disease.Journal of cellular and molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleCastleman disease (CD) is a rare lymphoproliferative disorder characterized by nonmalignant lymph node enlargement, often associated with systemic symptoms. It is classified into unicentric disease (involving a single enlarged lymph node) and multicentric disease (affecting multiple lymph node stations). In some cases of idiopathic multicentric Castleman disease (iMCD), elevated levels of various serum inflammatory markers are observed, and histologically, the lymph node enlargement resembles that caused by autoimmune diseases, making diagnosis challenging. PATIENT CONCERNS: A 35-year-old female patient presented with fatigue, low-grade fever, shoulder erythema, and generalized lymphadenopathy for 2 years. Persistent systemic inflammation, anemia, thrombocytosis, hypoalbuminemia, and hyperglobulinemia were noted. DIAGNOSES: Blood tests revealed systemic inflammation, including elevated levels of C-reactive protein and interleukin-6, along with increased rheumatoid factor levels. Computed tomography scans showed a large, well-defined mass with uniform enhancement in the left neck. Skin erythema pathology was suggestive of allergic purpura. Bone marrow biopsy showed increased plasma cells. Lymph node pathology revealed an increase in IgG4-positive cells, with a high number of CD38 and CD138 plasma cells, and the morphology was consistent with Castleman disease (plasmacytic type). The diagnosis was iMCD.
interventionsIntravenous tocilizumab (400 mg every 4 weeks), methylprednisolone (40 mg daily), and oral thalidomide (75 mg daily) were administered. Symptomatic treatment included intravenous albumin (10 g daily), topical application of denaseide cream (0.5 g twice daily) for rash and pruritus, oral cetirizine (10 mg daily), and oral ebastine (10 mg daily). OUTCOMES: The patient no longer experienced low-grade fever or fatigue but continued to have lymphadenopathy and shoulder erythema. LESSONS: This case highlights the rarity and uniqueness of iMCD, which can easily be confused with lymphadenopathy caused by autoimmune diseases (e.g., rheumatoid arthritis-related lymphadenopathy, IgG4-related diseases). Clinicians should consider lymph node histology in conjunction with clinical and serological findings, as well as imaging results, for accurate diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.